Citizens Financial Group Inc. RI Sells 553 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• Citizens Financial Group Inc. reduced its stake in Intuitive Surgical by 5.7%, selling 553 shares and bringing its total holdings to 9,116 shares, valued at approximately $4.5 million.
• Intuitive Surgical reported a 21.4% year-over-year revenue increase for the last quarter, with earnings per share of $2.19, exceeding analysts' expectations.
• Over 83% of Intuitive Surgical's stock is owned by institutional investors, and the majority of recent analyst ratings range from "hold" to "buy," with an average target price of $595.95.

Citizens Financial Group Inc. RI lessened its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 5.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,116 shares of the medical equipment provider's stock after selling 553 shares during the quarter. Citizens Financial Group Inc. RI's holdings in Intuitive Surgical were worth $4,515,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Parvin Asset Management LLC acquired a new position in shares of Intuitive Surgical in the 4th quarter worth $26,000. Chilton Capital Management LLC increased its stake in Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares in the last quarter. Global Financial Private Client LLC raised its holdings in Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after buying an additional 38 shares during the period. Elite Financial Inc. purchased a new stake in Intuitive Surgical during the first quarter valued at about $26,000. Finally, LFA Lugano Financial Advisors SA acquired a new position in shares of Intuitive Surgical in the first quarter worth about $30,000. Institutional investors own 83.64% of the company's stock.

Insider Activity

In other Intuitive Surgical news, insider Gary S. Guthart sold 2,800 shares of Intuitive Surgical stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $495.24, for a total value of $1,386,672.00. Following the transaction, the insider directly owned 18,520 shares of the company's stock, valued at $9,171,844.80. The trade was a 13.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mark Brosius sold 216 shares of the company's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president owned 907 shares of the company's stock, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,903 shares of company stock valued at $7,932,778. 0.70% of the stock is owned by insiders.

Analysts Set New Price Targets

ISRG has been the topic of a number of recent analyst reports. Citigroup restated a "buy" rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Royal Bank Of Canada raised their target price on Intuitive Surgical from $605.00 to $615.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 23rd. Truist Financial upped their price target on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Finally, Barclays decreased their price target on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Stock Up 0.1%

Shares of NASDAQ:ISRG traded up $0.27 during trading on Friday, reaching $470.08. The stock had a trading volume of 1,445,546 shares, compared to its average volume of 2,319,941. The stock has a fifty day simple moving average of $516.52 and a two-hundred day simple moving average of $528.79. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00. The firm has a market capitalization of $168.51 billion, a price-to-earnings ratio of 65.56, a P/E/G ratio of 4.93 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. Intuitive Surgical's revenue was up 21.4% compared to the same quarter last year. During the same period last year, the business posted $1.78 EPS. On average, analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.